Status:
COMPLETED
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Lead Sponsor:
Medtronic Spinal and Biologics
Conditions:
Radiculopathy
Myelopathy
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The purpose of this study is to establish the safety and effectiveness of the BRYAN(R) Cervical Disc Prosthesis in treating single-level degenerative disc disease of the cervical spine.
Detailed Description
Bryan(R) Cervical Disc Prosthesis is indicated in skeletally mature patients for reconstruction of the disc from C3 to C7 following single level discectomy for intractable radiculopathy and/or myelopa...
Eligibility Criteria
Inclusion
- The indication studied was degenerative disc disease (DDD) at a single level between C3 and C7 for any combination of disc herniation with radiculopathy, spondylotic radiculopathy, disc herniation with myelopathy, or spondylotic myelopathy.
- The following additional inclusion criteria had to be present:
- At least 6 weeks unsuccessful conservative treatment, except in cases of myelopathy requiring immediate treatment (e.g., acute onset of clinically significant signs);
- Requirement for surgical treatment demonstrated by CT, myelography and CT, and/or MRI;
- Skeletally mature (≥ 21 years of age);
- Preoperative Neck Disability Index score of ≥ 30 and at least one clinical sign associated with level to be treated;
- Willing to sign informed consent and comply with protocol.
Exclusion
- Subjects were excluded if they had any of the following:
- Any of the following at the treated level:
- Significant cervical anatomical deformity; e.g., ankylosing spondylitis, rheumatoid arthritis, etc.
- Moderate to advanced spondylosis. Patients who demonstrate advanced degenerative changes. Such advanced changes are characterized by any one or combination of the following: bridging osteophytes, marked reduction or absence of motion, collapse of the intervertebral disc space of greater than 50% of its normal height;
- Radiographic signs of subluxation greater than 3.5 mm;
- Angulation of the disc space more than 11 degrees greater than adjacent segments;
- Significant kyphotic deformity or significant reversal of lordosis;
- Axial neck pain as the solitary symptom;
- Previous cervical spine surgery;
- Metabolic bone disease, such as osteoporosis, defined as a BMD T-score equal to or worse than 2.5. If significant radiolucence is detected, a BMD scan in the spine, wrist, and femoral neck must be obtained.
- Active systemic infection or infection at the operative site;
- Known allergy or to titanium, polyurethane, or ethylene oxide residuals;
- Concomitant conditions requiring steroid treatment;
- Diabetes mellitus requiring daily insulin management;
- Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index;
- A medical condition that may interfere with the postoperative management program, such as advanced emphysema or Alzheimer's disease;
- A medical condition that may result in patient death prior to study completion: unstable cardiac disease, active malignancy;
- Pregnant;
- Current or recent alcohol and/or drug abuser requiring intervention;
- Signs of being geographically unstable, such as recent or pending divorce, or high level of job dissatisfaction.
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
494 Patients enrolled
Trial Details
Trial ID
NCT00437190
Start Date
June 1 2003
End Date
May 1 2016
Last Update
May 13 2016
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrow Neurosurgical Associates
Phoenix, Arizona, United States, 85013
2
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
3
Silicon Valley Spine Institute
Campbell, California, United States, 95008
4
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048